Skip to main content

Table 2 Summary table of the Italian data by hospital

From: Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016–2017 epidemic season: a systematic review of seven Italian reports

Season

Hospital

Population, n

Infants with bronchiolitis (30–35 wGA), n (%)

Infants with RSV (30–35 wGA), n (%)

Aged < 6 months, n (%)

Aged < 3 months, n (%)

HFNC, n (%)

Birth order, n (%)

2014–2015

“G. Gaslini” Instit. Genova

137 (RSV induced ALRI)

 

9 (6.6)

6 (66.7)

5 (55.6)

7 (77.8)

5 (55.6) first born

4 (44.4) not first born

2015–2016

“Umberto I” Hosp. Roma

152 (bronchiolitis)

14 (9.2)*

8 (57.1)

    

“G. Gaslini” Instit. Genova

109 (RSV induced ALRI)

 

8 (7.3)

3 (37.5)

3 (37.5)

2 (25)

8 (100) not first born

“Casilino” Hosp. Roma

35 (newborn 30–32 wGE)

6 (17)**

   

1 (16.7)

 

2016–2017

“Umberto I” Hosp. Roma

132 (bronchiolitis)

18 (13.6)*

12 (66.7)

    

“G. Gaslini” Instit. Genova

120 (RSV induced ALRI)

 

11 (9.2)

9 (81.8)

9 (81.8)

9 (81.8)

2 (18.2) first born

9 (81.8) not first born

“Casilino” Hosp. Roma

47 (newborn 30–32 wGE)

12 (25.5)**

   

2 (16.7)

 

2017–2018

“Casilino” Hosp. Roma

56 (newborn 30–32 wGE)

6 (10.7)

   

1 (16.7)

 
  1. HFNC = High Flow Nasal Canula; RSV = respiratory syncytial virus; wGA = weeks of gestational age. *P = 0.05; **P = 0.184